ArticlePLoS currents2010

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Teruhiko Terasawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.